Table of Contents
SRX Pharmacology
Volume 2010, Article ID 352491, 12 pages
http://dx.doi.org/10.3814/2010/352491
Review Article

Individualization of 5-Fluorouracil in the Treatment of Colorectal Cancer

Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh, 11495, Saudi Arabia

Received 14 October 2009; Accepted 24 November 2009

Copyright © 2010 Lamya Alnaim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. E. Evans and M. V. Relling, “Clinical pharmacokinetics-pharmacodynamics of anticancer drugs,” Clinical Pharmacokinetics, vol. 16, no. 6, pp. 327–336, 1989. View at Google Scholar
  2. E. Masson and W. C. Zamboni, “Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes,” Clinical Pharmacokinetics, vol. 32, no. 4, pp. 324–343, 1997. View at Google Scholar
  3. A. J. Galpin and W. E. Evans, “Therapeutic drug monitoring in cancer management,” Clinical Chemistry, vol. 39, no. 11, pp. 2419–2430, 1993. View at Google Scholar
  4. V. T. DeVita, “Principles of cancer management: chemotherapy,” in Cancer: Principles and Practice of Oncology, V. T. DeVita, S. Hellman, and S. A. Rosenberg, Eds., pp. 333–347, Lippincott, Philadelphia, Pa, USA, 5th edition, 1997. View at Google Scholar
  5. M. J. Moore and C. Erlichman, “Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy,” Clinical Pharmacokinetics, vol. 13, no. 4, pp. 205–227, 1987. View at Google Scholar
  6. J. H. Rodman and W. E. Evans, “Targeted systemic exposure for pediatric cancer therapy,” in Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, D. D'Argenio, Ed., pp. 177–183, Plenum Press, New York, NY, USA, 1991. View at Google Scholar
  7. M. W. Linder, R. A. Prough, and R. Valdes, “Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency,” Clinical Chemistry, vol. 43, no. 2, pp. 254–266, 1997. View at Google Scholar
  8. M. T. Zühlsdorf, “Relevance of pheno- and genotyping in clinical drug development,” International Journal of Clinical Pharmacology and Therapeutics, vol. 36, no. 11, pp. 607–612, 1998. View at Google Scholar
  9. E. Gamelin, M. Boisdron-Celle, V. Guérin-Meyer et al., “Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1105–1110, 1999. View at Google Scholar
  10. P. Houyau, C. Gay, E. Chatelut, P. Canal, H. Roche, and G. Milano, “Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency,” Journal of the National Cancer Institute, vol. 85, no. 19, pp. 1602–1603, 1993. View at Google Scholar
  11. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar
  12. M. Quinn, P. Babb, A. Brock, L. Kirby, and J. Jones, Cancer Trends in England and Wales 1950–1999, The Stationery Office, London, UK, 2008.
  13. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar
  14. T. Asano and R. S. McLeod, “Dietary fibre for the prevention of colorectal adenomas and carcinomas,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003430, 2002. View at Google Scholar
  15. K. B. Michels, E. Giovannucci, A. T. Chan, R. Singhania, C. S. Fuchs, and W. C. Willett, “Fruit and vegetable consumption and colorectal adenomas in the nurses' health study,” Cancer Research, vol. 66, no. 7, pp. 3942–3953, 2006. View at Publisher · View at Google Scholar · View at PubMed
  16. T. Norat, S. Bingham, P. Ferrari et al., “Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition,” Journal of the National Cancer Institute, vol. 97, no. 12, pp. 906–916, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. Y.-I. Kim, “Folate and colorectal cancer: an evidence-based critical review,” Molecular Nutrition and Food Research, vol. 51, no. 3, pp. 267–292, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. C. Dubé, A. Rostom, G. Lewin et al., “The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 365–375, 2007. View at Google Scholar
  19. A. Rostom, C. Dubé, G. Lewin et al., “Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force,” Annals of Internal Medicine, vol. 146, no. 5, pp. 376–389, 2007. View at Google Scholar
  20. J. A. Chan, J. A. Meyerhardt, A. T. Chan, E. L. Giovannucci, G. A. Colditz, and C. S. Fuchs, “Hormone replacement therapy and survival after colorectal cancer diagnosis,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5680–5686, 2006. View at Publisher · View at Google Scholar · View at PubMed
  21. T. Pischon, P. H. Lahmann, H. Boeing et al., “Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC),” Journal of the National Cancer Institute, vol. 98, no. 13, pp. 920–931, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. K. F. Adams, M. F. Leitzmann, D. Albanes et al., “Body mass and colorectal cancer risk in the NIH-AARP cohort,” American Journal of Epidemiology, vol. 166, no. 1, pp. 36–45, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. L. A. G. Ries, D. Melbert, M. Krapcho et al., Eds., SEER Cancer Statistics Review, 1975-2005, National Cancer Institute, Bethesda, Md, USA, 2008, http://seer.cancer.gov/csr/1975_2005/.
  24. J. Skibber, B. Minsky, and P. Hoff, “Cancer of the colon,” in Cancer: Principles and Practice of Oncology, V. DeVita, S. Hellman, and S. Rosenberg, Eds., pp. 1216–1270, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001. View at Google Scholar
  25. J. Skibber, P. Hoff, and B. Minsky, “Cancer of the rectum,” in Cancer: Principles and Practice of Oncology, V. DeVita, S. Hellman, and S. Rosenberg, Eds., pp. 1271–1318, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 6th edition, 2001. View at Google Scholar
  26. M. Buyse, A. Zeleniuch-Jacquotte, and T. C. Chalmers, “Adjuvant therapy of colorectal cancer. Why we still don't know,” Journal of the American Medical Association, vol. 259, no. 24, pp. 3571–3578, 1988. View at Google Scholar
  27. R. Labianca, S. Marsoni, G. Pancera et al., “Efficacy of adjuvant fluorouracil and folinic acid in colon cancer,” The Lancet, vol. 345, no. 8955, pp. 938–944, 1995. View at Publisher · View at Google Scholar
  28. N. Wolmark, H. Rockette, B. Fisher et al., “The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1879–1887, 1993. View at Google Scholar
  29. M. J. O'Connell, J. A. Mailliard, M. J. Kahn et al., “Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer,” Journal of Clinical Oncology, vol. 15, no. 1, pp. 246–250, 1997. View at Google Scholar
  30. A. de Gramont, J.-F. Bosset, C. Milan et al., “Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study,” Journal of Clinical Oncology, vol. 15, no. 2, pp. 808–815, 1997. View at Google Scholar
  31. P. Piedbois, “Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors,” Journal of Clinical Oncology, vol. 16, no. 11, pp. 3537–3541, 1998. View at Google Scholar
  32. A. B. P. van Kuilenburg, J. Haasjes, D. J. Richel et al., “Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene,” Clinical Cancer Research, vol. 6, no. 12, pp. 4705–4712, 2000. View at Google Scholar
  33. R. Meinsma, P. Fernandez-Salguero, A. B. P. van Kuilenburg, A. H. van Gennip, and F. J. Gonzalez, “Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea,” DNA and Cell Biology, vol. 14, no. 1, pp. 1–6, 1995. View at Google Scholar
  34. S. Takai, P. Fernandez-Salguero, S. Kimura, F. J. Gonzalez, and K. Yamada, “Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization,” Genomics, vol. 24, no. 3, pp. 613–614, 1994. View at Publisher · View at Google Scholar · View at PubMed
  35. N. Albin, M. R. Jonhson, H. Shahinian et al., “Initial characterization of the molecular defect in human dihydropyrimidine dehydrogenase deficiency,” Proceedings of the American Association for Cancer Research, vol. 36, p. 211A, 1995. View at Google Scholar
  36. “The NCCN Colon Cancer Clinical Practice Guidelines in Oncology (Version 2.2009),” National Comprehensive Cancer Network, Inc. 2009, http://www.nccn.org.
  37. S. T. Pullarkat, J. Stoehlmacher, V. Ghaderi et al., “Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy,” The Pharmacogenomics Journal, vol. 1, no. 1, pp. 65–70, 2001. View at Google Scholar
  38. S. Marsh, J. A. McKay, J. Cassidy, and H. L. McLeod, “Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer,” International Journal of Oncology, vol. 19, no. 2, pp. 383–386, 2001. View at Google Scholar
  39. G. Bocci, C. Barbara, F. Vannozzi et al., “A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity,” Clinical Pharmacology and Therapeutics, vol. 80, no. 4, pp. 384–395, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. G. Bocci, R. Danesi, A. Di Paolo et al., “Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients,” Clinical Cancer Research, vol. 6, no. 8, pp. 3032–3037, 2000. View at Google Scholar
  41. G. K. McEvoy, ed., “Fluorouracil,” in AHFS Drug Information, pp. 1020–1024, American Society of Health-System Pharmacists, Bethesda, Md, USA, 2005. View at Google Scholar
  42. H. Ezzeldin and R. Diasio, “Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration,” Clinical Colorectal Cancer, vol. 4, no. 3, pp. 181–189, 2004. View at Publisher · View at Google Scholar
  43. E. S. R. Collie-Duguid, M. C. Etienne, G. Milano, and H. L. McLeod, “Known variant DPYD alleles do not explain DPD deficiency in cancer patients,” Pharmacogenetics, vol. 10, no. 3, pp. 217–223, 2000. View at Google Scholar
  44. A. B. P. Van Kuilenburg, R. Meinsma, L. Zoetekouw, and A. H. Van Gennip, “High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity,” Pharmacogenetics, vol. 12, no. 7, pp. 555–558, 2002. View at Publisher · View at Google Scholar
  45. A. B. P. Van Kuilenburg, P. Vreken, L. V. A. M. Beex et al., “Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity,” Advances in Experimental Medicine and Biology, vol. 431, pp. 293–298, 1998. View at Google Scholar
  46. L. K. Mattison, R. Soong, and R. B. Diasio, “Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics,” Pharmacogenomics, vol. 3, no. 4, pp. 485–492, 2002. View at Publisher · View at Google Scholar · View at PubMed
  47. R. A. Fleming, G. Milano, A. Thyss et al., “Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients,” Cancer Research, vol. 52, no. 10, pp. 2899–2902, 1992. View at Google Scholar
  48. C. Katona, J. Kralovánszky, A. Rosta et al., “Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients,” Oncology, vol. 55, no. 5, pp. 468–474, 1998. View at Google Scholar
  49. Z. Lu, R. Zhang, and R. B. Diasio, “Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy,” Cancer Research, vol. 53, no. 22, pp. 5433–5438, 1993. View at Google Scholar
  50. M. R. Johnson, J. Yan, L. Shao, N. Albin, and R. B. Diasio, “Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity,” Journal of Chromatography B, vol. 696, no. 2, pp. 183–191, 1997. View at Publisher · View at Google Scholar
  51. M. C. Etienne, J. L. Lagrange, O. Dassonville et al., “Population study of dihydropyrimidine dehydrogenase in cancer patients,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2248–2253, 1994. View at Google Scholar
  52. G. Bocci, A. Di Paolo, C. Barbara et al., “Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction,” British Journal of Clinical Pharmacology, vol. 67, no. 1, pp. 132–134, 2009. View at Publisher · View at Google Scholar · View at PubMed
  53. B. E. Harris, R. Song, S.-J. Soong, and R. B. Diasio, “Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion,” Cancer Research, vol. 50, no. 1, pp. 197–201, 1990. View at Google Scholar
  54. A. Di Paolo, R. Danesi, A. Falcone et al., “Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients,” Annals of Oncology, vol. 12, no. 9, pp. 1301–1306, 2001. View at Publisher · View at Google Scholar
  55. H. Jiang, J. Lu, and J. Ji, “Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels,” British Journal of Pharmacology, vol. 141, no. 4, pp. 616–623, 2004. View at Publisher · View at Google Scholar · View at PubMed
  56. S. Sumi, K. Kidouchi, M. Kondou et al., “Possible prediction of adverse reactions to fluorouracil by the measurement of urinary dihydrothymine and thymine,” International Journal of Molecular Medicine, vol. 2, no. 4, pp. 477–482, 1998. View at Google Scholar
  57. A. H. van Gennip, N. G. Abeling, L. Elzinga-Zoetekouw, L. G. Scholten, A. van Cruchten, and H. D. Bakker, “Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency,” Advances in Experimental Medicine and Biology, vol. 253A, pp. 111–118, 1989. View at Google Scholar
  58. J. F. Seitz, J. P. Cano, J. P. Rigault et al., “Chimiothérapie des cancers digestifs étendus par le 5-fluorouracile: relations entre la réponse clinique et la clairance plasmatique du medicament,” Gastroenterologie Clinique et Biologique, vol. 7, no. 4, pp. 374–380, 1983. View at Google Scholar
  59. E. C. Gamelin, E. M. Danquechin-Dorval, Y. F. Dumesnil et al., “Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU,” Cancer, vol. 77, no. 3, pp. 441–451, 1996. View at Publisher · View at Google Scholar
  60. E. Gamelin, M. Boisdron-Celle, R. Delva et al., “Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1470–1478, 1998. View at Google Scholar
  61. M. Ychou, J. Duffour, A. Kramar et al., “Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 4, pp. 282–290, 2003. View at Publisher · View at Google Scholar · View at PubMed
  62. G. Milano, M. C. Etienne, N. Renée et al., “Relationship between fluorouracil systemic exposure and tumor response and patient survival,” Journal of Clinical Oncology, vol. 12, no. 6, pp. 1291–1295, 1994. View at Google Scholar
  63. R. Fety, F. Rolland, M. Barberi-Heyob et al., “Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas,” Clinical Cancer Research, vol. 4, no. 9, pp. 2039–2045, 1998. View at Google Scholar
  64. M. Boisdron-Celle, G. Remaud, S. Traore et al., “5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency,” Cancer Letters, vol. 249, no. 2, pp. 271–282, 2007. View at Publisher · View at Google Scholar · View at PubMed
  65. A. Thyss, G. Milano, N. Renée, J. Vallicioni, M. Schneider, and F. Demard, “Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer,” Cancer Chemotherapy and Pharmacology, vol. 16, no. 1, pp. 64–66, 1986. View at Google Scholar
  66. C. J. Van Groeningen, H. M. Pinedo, J. Heddes et al., “Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule,” Cancer Research, vol. 48, no. 23, pp. 6956–6961, 1988. View at Google Scholar
  67. D. L. Trump, M. J. Egorin, A. Forrest, J. K. V. Willson, S. Remick, and K. D. Tutsch, “Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole,” Journal of Clinical Oncology, vol. 9, no. 11, pp. 2027–2035, 1991. View at Google Scholar
  68. D. I. Jodrell, M. Stewart, R. Aird et al., “5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer,” British Journal of Cancer, vol. 84, no. 5, pp. 600–603, 2001. View at Publisher · View at Google Scholar · View at PubMed
  69. J. Santini, G. Milano, A. Thyss et al., “5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer,” British Journal of Cancer, vol. 59, no. 2, pp. 287–290, 1989. View at Google Scholar
  70. E. E. Vokes, R. Mick, M. S. Kies et al., “Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer,” Journal of Clinical Oncology, vol. 14, no. 5, pp. 1663–1671, 1996. View at Google Scholar
  71. E. Gamelin, J. Jacob, E. Danquechin-Dorval et al., “Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area,” in Annual Meeting of American Society of Clinical Oncology, Alexandria, Va, USA, 1998, abstract no. 1039.
  72. A. Di Paolo, M. Lencioni, F. Amatori et al., “5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer,” Clinical Cancer Research, vol. 14, no. 9, pp. 2749–2755, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. E. Gamelin, R. Delva, J. Jacob et al., “Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2099–2105, 2008. View at Publisher · View at Google Scholar · View at PubMed
  74. M. J. Moore, P. Bunting, S. Yuan, and J. J. Thiessen, “Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration,” Therapeutic Drug Monitoring, vol. 15, no. 5, pp. 394–399, 1993. View at Google Scholar
  75. A. Di Paolo, R. Danesi, F. Vannozzi et al., “Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer,” Clinical Pharmacology and Therapeutics, vol. 72, no. 6, pp. 627–637, 2002. View at Publisher · View at Google Scholar · View at PubMed
  76. M. Schneider, M. C. Etienne, G. Milano et al., “Phase II trial of cisplatin, fluorouracil, and pure/folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1656–1662, 1995. View at Google Scholar
  77. R.-J. Bensadoun, M.-C. Etienne, O. Dassonville et al., “Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study,” International Journal of Radiation Oncology Biology Physics, vol. 42, no. 2, pp. 237–245, 1998. View at Publisher · View at Google Scholar